Abstract 189P
Background
Malignant tumors are sophisticated, organized ecosystems in addition to collections of cancer cells. It has long been established that the formation, recurrence, and metastasis of cancers are all tightly correlated with their immune components. However, the impact of the tumor microenvironment in soft tissue sarcoma (STS) remains mainly unclear. Studying how the immunological microenvironment affects the clinical presentation and prognosis of soft tissue sarcomas is the objective.
Methods
Retrospective research was conducted on 168 soft tissue sarcoma patients who received care at the Republican specialized Scientific and practical Medical Center of Oncology and Radiology of Uzbekistan. Through immunohistochemistry analyses of CD3, CD4, CD8, CD20, and CD68, lymphocyte subpopulations that infiltrate tumours and their subpopulations were investigated.
Results
In the immunological microenvironment, CD 68+ macrophages and CD 3+ T cells were the most prevalent cell types. There was a substantial positive correlation between CD 68 expression and the probability of local recurrence (p = 0.014) in a multivariate analysis employing the Fine & Gray risk regression model with death as a competing event, independent of age, resection margins, and the presence of B cells. Furthermore, B cell abundance was significantly lower (p = 0.013) and macrophage abundance was much higher in patients older than middle age. Regarding histological subtypes, undifferentiated pleomorphic sarcoma and myxofibrosarcoma were more frequently found to have these cells, which had a high total number of tumor-infiltrating lymphocytes in general and macrophages in particular.
Conclusions
The significant number of CD 68 macrophages in soft tissue sarcomas and their detrimental effect on the prognosis for local recurrence are both confirmed by this investigation.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
90P - HAIC plus sintilimab and bevacizumab biosimilar as treatment for patients with advanced hepatocellular carcinoma (HCC): a phase II trial
Presenter: HAIBIN ZHANG
Session: Poster Display
91P - A real-world study of tislelizumab (Anti-PD-1) plus tyrosine kinase inhibitors for intermediate or advanced hepatocellular carcinoma
Presenter: Wei zhang
Session: Poster Display
92P - TAE-HAIC plus lenvatinib and PD-1 inhibitors versus TAE-HAIC plus atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: A propensity score matching study
Presenter: hongjie Cai
Session: Poster Display
93P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: a real-world, retrospective, multicentric study.
Presenter: Margherita Rimini
Session: Poster Display
94P - First-line chemotherapy plus immunotherapy versus chemotherapy alone for advanced gallbladder carcinoma
Presenter: Qin-qin Liu
Session: Poster Display
95P - A single-arm, multicenter phase ? trial evaluating TQB2450 plus anlotinib combined with paclitaxel and cisplatin in first-line treatment of advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Junsheng Wang
Session: Poster Display
97P - ICI for patients with MSS metastatic colorectal cancer
Presenter: Zayana Sangadzhieva
Session: Poster Display
Resources:
Abstract
99P - Efficacy and safety of toripalimab plus metronomic chemotherapy in HER2 negative metastatic breast cancer
Presenter: Hongnan Mo
Session: Poster Display